Locations:
SearchAdvertisement
Cleveland Clinic is a non-profit academic medical center. Advertising on our site helps support our mission. We do not endorse non-Cleveland Clinic products or services. Policy
Disease: Leukemia
Objective: The primary objective is to determine a possible maximum tolerated dose (MTD, defined in Section 7.1.1) for KB004 when administered up to 700 mg once weekly by IV infusion to subjects with hematologic malignancies.
Disease: Myelodysplastic Syndrome (MDS)
Objective: The primary objective is to Estimate Clinical Improvement rate including Complete Responses (CR), Marrow CR, Partial Responses (PR), Hematologic Improvement (HI) (CR+Marrow CR+PR+HI).
Disease: Myelodysplastic Syndrome (MDS)
Objective: The primary objective is to estimate the relative efficacy, as measured by CR at or before the Cycle 6 response assessment following randomization of pracinostat plus azacitidine versus placebo plus azacitidine.
Disease: Lung
Objective: The primary objective is to evaluate the efficacy of MPDL3280A in patients with PD-L1- positive locally advanced or metastatic NSCLC.
Photo by Russell Lee
Advertisement
Advertisement
First-of-its-kind research investigates the viability of standard screening to reduce the burden of late-stage cancer diagnoses
Study demonstrates ability to reduce patients’ reliance on phlebotomies to stabilize hematocrit levels
Findings highlight an association between obesity and an increased incidence of moderate-severe disease
Cleveland Clinic Cancer Institute takes multi-faceted approach to increasing clinical trial access 23456
Key learnings from DESTINY trials
Gene editing technology offers promise for treating multiple myeloma and other hematologic malignancies, as well as solid tumors
Study of 401,576 patients reveals differences in cancer burdens as well as overall survival
Enfortumab plus pembrolizumab reduced risk of death by 53% compared with platinum-based chemotherapy
